ReviewFrontiers in oncology2025
New highlights in cancer and depression multimorbidity: a scoping systematic review.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The co-occurrence of cancer and depression represents a prevalent and clinically significant form of multimorbidity, associated with poorer prognosis and increased healthcare burden. Despite this, current care models often operate in silos, resulting in fragmented management between oncology and psychiatry. This scoping review systematically maps existing evidence on cancer-depression multimorbidity to clarify epidemiological associations, elucidate underlying pathophysiological mechanisms, and synthesize integrated management strategies. Methods: The review followed the Joanna Briggs Institute methodology for scoping reviews and adhered to the PRISMA-ScR reporting guidelines. A systematic search was conducted across four electronic databases (PubMed, Scopus, Web of Science, and Embase) for studies published between 2020 and 2025. Eligible studies included adult populations with cancer-depression multimorbidity, addressing epidemiology, mechanisms, or management outcomes. Results: From 11,803 initial records, 36 studies met the inclusion criteria. The evidence consistently indicates a significant association between depression and increased risk of both all-cause and cancer-specific mortality across multiple cancer types. The included studies demonstrated notable heterogeneity in depression assessment methods and a geographical concentration in Asia, Europe, and North America. Discussion: This scoping review establishes a substantial and consistent body of evidence linking depression to elevated mortality risk in patients with cancer, identifying depression as a critical and modifiable prognostic factor. The synthesis highlights key evidence gaps, including the underrepresentation of low- and middle-income countries and variability in depression measurement. These findings emphasize the need for systematic integration of depression screening and management into routine oncologic care and call for future research to develop standardized assessment tools and culturally adapted intervention models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.